樂觀
$245.24
情境價格
$222.660
-1.648 (-0.74%)收盤時
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
STERIS plc is a good buy right now due to its current price of $222.66, which is below the analyst price target of $275 from UBS, indicating significant upside potential. Additionally, the company has shown a strong gross margin of 43.89% in the latest quarter, reflecting solid profitability. However, the main risk is the recent decline in free cash flow, which dropped to $279.6 million from $326.5 million year-over-year, highlighting potential cash management challenges.
UBS
$275
2026-07-28
UBS
2026-07-28
目標價
$275
KeyBanc
$269
2026-05-13
KeyBanc
2026-05-13
目標價
$269
Morgan Stanley
—
2026-01-08
Morgan Stanley
2026-01-08
目標價
—
JPMorgan
—
2025-12-05
JPMorgan
2025-12-05
目標價
—
KeyBanc
$288
2025-07-22
KeyBanc
2025-07-22
目標價
$288
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

STERIS Acquires Xodus Medical for $2.1 Billion

STERIS plc Reports First Quarter Earnings Growth

Steris Reports Q1 2027 Earnings with Mixed Results

STERIS Reports Strong Q1 2027 Financial Results with Strategic Restructuring

STERIS Announces Quarterly Dividend Increase to $0.69
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
STERIS plc is a good buy right now due to its current price of $222.66, which is below the analyst price target of $275 from UBS, indicating significant upside potential. Additionally, the company has shown a strong gross margin of 43.89% in the latest quarter, reflecting solid profitability. However, the main risk is the recent decline in free cash flow, which dropped to $279.6 million from $326.5 million year-over-year, highlighting potential cash management challenges.
8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。